Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

June 03, 2015 4:36 PM ET

Healthcare Equipment and Supplies

Company Overview of Bausch & Lomb Incorporated

Company Overview

Bausch & Lomb Incorporated develops, manufactures, and markets eye care products. It focuses on protecting, enhancing, and restoring people’s eyesight. The company offers contact and hydrophobic acrylic intraocular lenses; contact lens care, dry eye, allergy/redness relief, Rx pharmaceutical, and surgical products; and eye vitamins, vision accessories, and safety and industrial cleaning products. It also offers contract manufacturing services for sterile and non-sterile solutions, suspensions, ointments, gels, creams, nasals, and injectables. The company was formerly known as Bausch & Lomb Optical Company and changed its name to Bausch & Lomb Incorporated in March 1960. The company was found...

1400 North Goodman Street

Rochester, NY 14609

United States

Founded in 1853

13,000 Employees





Key Executives for Bausch & Lomb Incorporated

President of Asia-Pacific
Age: 69
Corporate Vice President and President of Latin America Operations
Executive Vice President of Global Business Operations & Process Excellence and Corporate Vice President
Chief Medical Officer and Executive Vice President
Age: 62
Head of Sales for US Vision Care Division
Compensation as of Fiscal Year 2014.

Bausch & Lomb Incorporated Key Developments

Bausch + Lomb Announces the Availability of its Enhanced TRULIGN Toric Intraocular Lens Calculator

Bausch + Lomb announced it has launched a number of enhancements to its TRULIGN Toric intraocular lens (IOL) calculator, which is designed to allow surgeons to successfully select the appropriate IOL power range for cataract patients. The enhanced calculator will further streamline the TRULIGN Toric IOL fitting process by providing enhancements that make it easier-to-use, convenient and ccessible for surgeons and technicians. The TRULIGN Toric calculator is a tool which assists surgeons with TRULIGN Toric IOL selection by directly entering the patient's flat (K1/axis) and steep (K2/axis) figures, including Surgically Induced Astigmatism (SIA), incision location, and IOL mean sphere power information. Directly following this step, the calculator provides the lens selection specifications including chosen mean sphere power, calculated IOL cylinder power, in addition to the full calculation summary including the pre-op corneal astigmatism, SIA, expected post-op corneal astigmatism, and residual astigmatism data. In addition to providing a more easy-to-use and simplified design, the new enhancements will allow surgeons to immediately calculate the steep axis from the data entered in the flat axis section, perform concurrent bilateral calculations, and view the axis of placement located in the center of eye and the residual astigmatism clearly located in the eye diagram.

Bausch & Lomb Incorporated to Invest 75 Million in Waterford Plant, Generating 125 Job Opportunities

Bausch & Lomb Incorporated expected to generate 125 job opportunities at its Waterford facility in Ireland. B&L proposes to add 112,000 sq ft of new manufacturing space on a 17-acre site located near the existing plant. The development has received planning permission, which would also create 150 construction jobs. This investment is expected to even boost the Waterford facilities ability to support the contact lens manufacturer as it is in efforts to raise its share in the contact lens market.

Bausch + Lomb Announces Availability of Enhanced BLIS Reusable Injector System for enVista Intraocular Lenses

Bausch + Lomb announced the availability of an enhanced BLIS Injector System, which is designed exclusively for use with the enVista, hydrophobic acrylic intraocular lens (IOL). With the new enhancements, eye care practitioners will be provided even greater control, allowing safe delivery of the enVista IOL through unenlarged phaco incisions as small as 2.2 mm. The BLIS injector system was first introduced in February 2014 and features a reusable hand piece made of high-quality, titanium material designed for both reliability and comfort. The proprietary disposable cartridge is designed for easy lens loading and wound entry and smooth delivery of enVista. The enhanced BLIS now includes a softened and tumble-polished plunger tip that is 2mm longer than the previous design, which helps facilitate easier placement in the capsular bag, in addition to several other features to ensure a seamless, positive customer experience.

Similar Private Companies By Industry

Company Name Region
Putnam Plastics Company, LLC United States
FzioMed, Inc. United States
NICO Corporation United States
Creative Bioreactor Designs, Inc. United States
Consensus Orthopedics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Bausch & Lomb Incorporated, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at